Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Glaukos Corp
(NY:
GKOS
)
140.83
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glaukos Corp
< Previous
1
2
3
4
5
6
7
8
9
Next >
Glaukos Announces Participation in Upcoming Investor Conferences
November 08, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
November 05, 2024
Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds.
Via
Benzinga
Glaukos Announces Third Quarter 2024 Financial Results
November 04, 2024
From
Glaukos Corporation
Via
Business Wire
How Is The Market Feeling About Glaukos?
October 30, 2024
Via
Benzinga
Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
October 16, 2024
From
Glaukos Corporation
Via
Business Wire
A Closer Look at 7 Analyst Recommendations For Glaukos
October 14, 2024
Via
Benzinga
Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting
October 14, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
October 09, 2024
From
Glaukos Corporation
Via
Business Wire
Navigating 11 Analyst Ratings For Glaukos
August 28, 2024
Via
Benzinga
Glaukos Announces Participation in Upcoming Investor Conferences
August 16, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)
August 01, 2024
Via
Benzinga
10 Analysts Have This To Say About Glaukos
July 10, 2024
Via
Benzinga
Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)
May 22, 2024
Via
Benzinga
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
August 01, 2024
Via
Benzinga
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q2 2024
July 31, 2024
GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Glaukos Announces Second Quarter 2024 Financial Results
July 31, 2024
From
Glaukos Corporation
Via
Business Wire
7 Leading MedTech Stocks for Next-Gen Health Solutions
July 31, 2024
With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar.
Via
InvestorPlace
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
July 10, 2024
Via
Benzinga
Analyst Ratings For Glaukos
April 08, 2024
Via
Benzinga
Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31
July 10, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
June 14, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Upcoming Investor Conferences
May 28, 2024
From
Glaukos Corporation
Via
Business Wire
Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst
May 02, 2024
Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%.
Via
Benzinga
Topics
Earnings
Exposures
Financial
C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
May 02, 2024
Via
Benzinga
GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024
May 01, 2024
GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Glaukos Announces First Quarter 2024 Financial Results
May 01, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces the Release of its 2023 Sustainability Report
April 16, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
April 10, 2024
From
Glaukos Corporation
Via
Business Wire
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
April 03, 2024
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
April 03, 2024
From
Glaukos Corporation
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.